Herbert A. Eradat, MD

Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses data with acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unprecedented aspects of the phase II CAPTIVATE trial in chronic lymphocytic leukemia (CLL).

Herbert A. Eradat, MD, associate professor, University of California, Los Angeles Medical Center, discusses unmet needs in chronic lymphocytic leukemia.

Herbert A. Eradat, MD, compares novel therapies with cytotoxic chemotherapy in the treatment of patients with chronic lymphocytic leukemia.